Bruxism is a parafunctional activity and over time it leads to hypertrophy of masseter muscles which can cause a square appearance of face profile and myofacial pain as well. There are surgical and non-surgical methods to treat the masseter hypertrophy. Botulinum toxin injection into the muscle is a safe and effective non-surgical method in the management of hypertrophy. It is also important to monitor the region of interest by one imaging method such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasonography (USG) or face scan. Aim of this case report is to demonstrate the effectiveness of USG and face scan procedures in the follow-up of masseter hypertrophy treatment by Botulinum toxin type-A injection.
Keywords: Bruxism; ultrasonography; face scan
Bruksizm, parafonksiyonel bir aktivitedir ve zamanla masseter kaslarının hipertrofisine yol açarak, yüz profilinde kare görünüme ve miyofasiyal ağrıya neden olur. Masseter hipertrofisini tedavi etmek için cerrahi ve cerrahi olmayan yöntemler vardır. Kas içine Botulinum toksini enjeksiyonu, hipertrofi tedavisinde güvenli ve etkili bir cerrahi olmayan yöntemdir. İlgilenilen bölgeyi manyetik rezonans görüntüleme (MRG), bilgisayarlı tomografi (BT), ultrasonografi (USG) veya yüz taraması gibi bir görüntüleme yöntemiyle izlemek de önemlidir. Bu olgu sunumunun amacı, USG ve yüz tarama prosedürlerinin, Botulinum toksin tip-A enjeksiyonuyla yapılan masseter hipertrofisi tedavisinin izlenmesinde etkinliğini göstermektir.
Anahtar Kelimeler: Diş gıcırdatma; ultrasonografi; yüz tarama
- von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107(2):327-32. [Crossref] [PubMed]
- Nissan J, Gross MD, Shifman A, Tzadok L, Assif D. Chewing side preference as a type of hemispheric laterality. J Oral Rehabil. 2004;31(5):412-6. [Crossref] [PubMed]
- Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscles. Am J Surg. 1947;73(1):137-9. [Crossref] [PubMed]
- Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115(3):919-30. [Crossref] [PubMed]
- Maxwell JH, Waggoner RW. Hypertrophy of the masseter muscles. Trans Am Laryngol Assoc. 1952;53(72nd Meeting):193-204. [PubMed]
- Lee HJ, Kim SJ, Lee KJ, Yu HS, Baik HS. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: a longitudinal study. Korean J Orthod. 2017;47(4):222-8. [Crossref] [PubMed] [PMC]
- Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1-2):10-24. [Crossref] [PubMed] [PMC]
- Chang CS, Lin S, Wallace CG, Hsiao YC, Lin CM, Kang GCW, et al. Masseter muscle volume changes evaluated by 3-dimensional computed tomography after repeated botulinum toxin a injections in patients with square facial morphology. Ann Plast Surg. 2019;82(1S Suppl 1):S29-32. [Crossref] [PubMed]
- Kim KS, Byun YS, Kim YJ, Kim ST. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle. Dermatol Surg. 2009;35(12):1902-6. [Crossref] [PubMed]
- Yu CC, Chen PKT, Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plast Surg. 2007;31(5):445-51. [Crossref] [PubMed]
- Morris DE, Moaveni Z, Lo LJ. Aesthetic facial skeletal contouring in the Asian patient. Clin Plast Surg. 2007;34(3):547-56. [Crossref] [PubMed]
- To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200. [Crossref] [PubMed]
- Castro WH, Gomez RS, da Silva Oliveira J, Moura MDG, Gomez RS. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg. 2005;63(1):20-4. [Crossref] [PubMed]
- Andrade NN, Deshpande GS. Use of botulinum toxin (botox) in the management of masseter muscle hypertrophy: a simplified technique. Plast Reconstr Surg. 2011;128(1):24e-6e. [Crossref] [PubMed]
- Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI. Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg. 2007;120(3):769-78. [Crossref] [PubMed]
- Chang CS, Kang GCW. Achieving ideal lower face aesthetic contours: combination of tridimensional fat grafting to the chin with masseter botulinum toxin injection. Aesthet Surg J. 2016;36(10):1093-100. [Crossref] [PubMed]
- Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29(5):484-9. [Crossref] [PubMed]
- Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119(2):711-7. [Crossref] [PubMed]
- Zhao YJ, Xiong YX, Wang Y. Three-dimensional accuracy of facial scan for facial deformities in clinics: a new evaluation method for facial scanner accuracy. PLoS One. 2017;12(1):e0169402. [Crossref] [PubMed] [PMC]
- Zhao YJ, Xiong YX, Yang HF, Wang Y. [Evaluation of measurement accuracy of three facial scanners based on different scanning principles]. Beijing Da Xue Xue Bao Yi Xue Ban. 2014;46(1):76-80. [PubMed]
- Liu Y, Ma LL, Chen S, Xu TM. [Accuracy of three-dimensional facial image based on phase measuring profilometry]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2007;42(1):37-40. [PubMed]
- Ferrario VF, Sforza C, Dellavia C, Tartaglia GM, Colombo A, Carù A. A quantitative three-dimensional assessment of soft tissue facial asymmetry of cleft lip and palate adult patients. J Craniofac Surg. 2003;14(5):739-46. [Crossref] [PubMed]
- Meyer-Marcotty P, Alpers GW, Gerdes ABM, Stellzig-Eisenhauer A. Impact of facial asymmetry in visual perception: a 3-dimensional data analysis. Am J Orthod Dentofacial Orthop. 2010;137(2):168.e1-8. [Crossref] [PubMed]
- Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003;29(5):477-83. [Crossref] [PubMed]
- Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31(5):502-7. [Crossref] [PubMed]
- Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125(6):1693-705. [Crossref] [PubMed]
- Lee SH, Wee SH, Kim HJ, Yeo UC, Lee NH, Lee SW, et al. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. J Dermatolog Treat. 2013;24(2):133-6. [Crossref] [PubMed]
- Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Lektrakul N, Manuskiatti W. The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study. J Dermatol Treat. 2017;28(5):443-6. [Crossref] [PubMed]
- Lee DH, Jin SP, Cho S, Feneran A, Youn CS, Won CH, et al. RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study. Dermatology. 2013;226(3):227-32. [Crossref] [PubMed]
.: Process List